Semaglutide Weight Loss: Expert Reaction to New Studies
- Two studies published in The Lancet Diabetes & Endocrinology examine the impact of increased semaglutide dosages on weight reduction in obese adults.
- The research suggests that a weekly injection of a higher semaglutide dose (7.2 mg) may lead to greater therapeutic benefits for patients with obesity and type 2 diabetes...
- the studies, conducted across different countries and including participants from various nationalities, revealed that the 7.2 mg dose of semaglutide resulted in an average weight loss of 18.7%...
“`html
higher Dose Semaglutide Demonstrates Critically important Weight Loss in Obesity Trials
Table of Contents
Two studies published in The Lancet Diabetes & Endocrinology examine the impact of increased semaglutide dosages on weight reduction in obese adults.
The research suggests that a weekly injection of a higher semaglutide dose (7.2 mg) may lead to greater therapeutic benefits for patients with obesity and type 2 diabetes compared to current dosages.
Study Findings: Semaglutide at 7.2mg
the studies, conducted across different countries and including participants from various nationalities, revealed that the 7.2 mg dose of semaglutide resulted in an average weight loss of 18.7% compared to a placebo. Approximately half of the patients experienced a weight loss of 20% or more during the study period.
However, the higher dose was associated with more frequent and pronounced side effects, particularly gastrointestinal issues such as nausea, vomiting, and constipation, compared to the placebo group.
analysis indicates that the majority of weight loss achieved with semaglutide was attributable to a reduction in body fat. Further research is needed to determine if the higher degree of weight loss also leads to a loss of muscle mass.
It’s important to note that the 7.2 mg dose used in these studies is substantially higher than the currently approved maximum dose of 2.0-2.4 mg, which has undergone rigorous safety testing.
Expert Commentary
Professor Lora Heisler, Director of Research, Rowett Institute, University of Aberdeen
“This study investigated whether a once weekly injection with a higher dose of semaglutide (the active ingredient of Wegovy and Ozempic) produced greater therapeutic benefits for patients living with obesity and type 2 diabetes compared to current doses. Advantages of the two studies is that they were conducted in different countries and included participants with different nationalities. What they found is that the higher dose of semaglutide (7.2 mg) led to an average of 18.7% weight loss compared with placebo. Around half of patients lost 2
Worth a look